SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical device technology company
focused on developing products to diagnose and treat life and organ
threatening diseases, today announced that Timothy C. Rodell, M.D., Chief Executive
Officer, is scheduled to provide an overview of the Company on
Monday, Sept. 14, at 2:00 p.m. EDT
Replays of the presentation will be aired live and available for
90 days. The reply can be accessed at
https://wsw.com/webcast/hcw7/aemd/1577311 and the investor
relations section of Aethlon Medical's website at
www.aethlonmedical.com.
About Aethlon Medical, Inc. and the
Hemopurifier®
Aethlon is focused on addressing
unmet needs in global health. The Aethlon Hemopurifier is a
clinical- stage immunotherapeutic device designed to combat cancer
and life-threatening viral infections. In cancer, the Hemopurifier
is designed to deplete the presence of circulating tumor-derived
exosomes that promote immune suppression.
These tumor derived exosomes also seed the spread of metastases
and inhibit the benefit of leading cancer therapies. The
Hemopurifier® is an FDA designated "Breakthrough Device"
related to the treatment of individuals with advanced or metastatic
cancer who are either unresponsive to or intolerant of standard of
care therapy, and with cancer types in which exosomes have been
shown to participate in the development or severity of the disease
cancer. The Hemopurifier also holds a Breakthrough Device
designation related to life-threatening viruses that are not
addressed with approved therapies.
Aethlon also owns 80% of Exosome Sciences, Inc., which is
focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Media Contact:
Tony
Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-22nd-annual-global-investment-conference-301124812.html
SOURCE Aethlon Medical, Inc.